{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.5","upperLimit":"40","value":"23"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Percentage of participants who were alive and progression free at 24 weeks. The 24 week progression free survival, with 95% confidence interval, was estimated using the Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma","id":"OG000","title":"Dasatinib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"24 Week Progression Free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}